This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
Low Carb Breckenridge 2017 is open to all including the general public, health, nutrition and fitness enthusiasts, scientific community and healthcare professionals.

For healthcare professionals, this live activity, Low Carb Breckenridge 2017, with a beginning date of 02/24/2017, has been reviewed and is acceptable for up to 19.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Event Page: http://denversdietdoctor.com/low-carb-breckenridge-2017/
View analytic
Saturday, February 25 • 9:30am - 10:00am
Carbohydrate Restriction in Cancer Therapy (CME Approved)

Sign up or log in to save this to your schedule and see who's attending!

Feedback form is now closed.
Observational data from studies at Harvard, UCSD, and Stanford associate moderate carbohydraterestriction with substantial improvements in recurrence risk and survival in postmenopausal breast cancer and stageIII colorectal cancer. Carbohydrate restriction is inappropriate for almost all pediatric tumors and many adult tumors.

Preclinical data show promise for a ketogenic diet in various tumors, including glioblastoma multiforme. Intermittentenergy restriction during cancer therapy is also undergoing intense clinical investigation due to strong preclinicalevidence that it potentiates the effectiveness of both chemotherapy and radiation therapy. Preclinical work showsthat the mechanism behind these effects involves energy-sensing pathways resulting in salutary modulation of theinsulin/IGF1 axis. Moderate carbohydrate restriction of 100 grams daily in postmenopausal hormone-receptorpositive breast cancer and stage III colorectal cancer is evidence-backed, reduces insulin exposure, and allows anormal lifestyle. Preclinical work suggests efficacy for the ketogenic diet in animal models of glioblastoma. Theketogenic diet is safe in certain populations and clinical trials are underway, but these have not yet establishedconsistent efficacy in humans with glioblastoma. Similarly, intermittent energy restriction is safe for most patients,but must be used with care in those with the advanced inflammatory syndrome of cancer cachexia, characterized byloss of lean tissue and extreme insulin resistance. Those patients, however, may benefit from the high-fat ketogenicdiet.


Saturday February 25, 2017 9:30am - 10:00am
1) Forrest Room